Ban of colistin livestock feed supplementation decreased the prevalence of colistin-resistant Escherichia coli in Ecuador.

IF 1.9 4区医学 Q3 INFECTIOUS DISEASES

Journal of Infection and Chemotherapy Pub Date : 2025-03-18 DOI:10.1016/j.jiac.2025.102682

Hoa Thi Thanh Hoang, Mayumi Yamamoto, Manuel Calvopina, Carlos Bastidas-Caldes, Diep Thi Khong, Thang Nam Nguyen, Yoshimasa Yamamoto

{"title":"Ban of colistin livestock feed supplementation decreased the prevalence of colistin-resistant Escherichia coli in Ecuador.","authors":"Hoa Thi Thanh Hoang, Mayumi Yamamoto, Manuel Calvopina, Carlos Bastidas-Caldes, Diep Thi Khong, Thang Nam Nguyen, Yoshimasa Yamamoto","doi":"10.1016/j.jiac.2025.102682","DOIUrl":null,"url":null,"abstract":"Objectives: In 2019, Ecuador implemented a ban on colistin feed supplementation owing to the increasing prevalence of colistin-resistant bacteria; however, the impact of this ban remains unclear.Methods: In this study, we aimed to elucidate the effects of the 2019 colistin ban by comparing the prevalence of colistin-resistant Escherichia coli in Ecuador with that in Vietnam, where colistin use is still permitted. We isolated colistin-resistant E. coli from the fecal samples of residents and detected mobile colistin resistance (mcr) genes in both the fecal samples and isolates.Results: Prevalence of colistin-resistant E. coli significantly decreased from 80.6 % in 2019 (n = 139) to 4.7 % in 2022 (n = 106) in Ecuador. Meanwhile, colistin-resistant E. coli prevalence only decreased from 84.7 % in 2017 (n = 98) to 62 % in 2024 (n = 50) in Vietnam. Notably, 96.8 % of the colistin-resistant E. coli isolates in Vietnam carried the mcr genes in 2024, whereas only 4.7 % of the isolates in Ecuadorian fecal samples harbored these genes in 2023.Conclusions: Overall, our findings highlight the significant impact of colistin use regulations on the decreased prevalence of colistin-resistant E. coli among Ecuadorian residents.","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":"102682"},"PeriodicalIF":1.9000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jiac.2025.102682","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: In 2019, Ecuador implemented a ban on colistin feed supplementation owing to the increasing prevalence of colistin-resistant bacteria; however, the impact of this ban remains unclear.

Methods: In this study, we aimed to elucidate the effects of the 2019 colistin ban by comparing the prevalence of colistin-resistant Escherichia coli in Ecuador with that in Vietnam, where colistin use is still permitted. We isolated colistin-resistant E. coli from the fecal samples of residents and detected mobile colistin resistance (mcr) genes in both the fecal samples and isolates.

Results: Prevalence of colistin-resistant E. coli significantly decreased from 80.6 % in 2019 (n = 139) to 4.7 % in 2022 (n = 106) in Ecuador. Meanwhile, colistin-resistant E. coli prevalence only decreased from 84.7 % in 2017 (n = 98) to 62 % in 2024 (n = 50) in Vietnam. Notably, 96.8 % of the colistin-resistant E. coli isolates in Vietnam carried the mcr genes in 2024, whereas only 4.7 % of the isolates in Ecuadorian fecal samples harbored these genes in 2023.

Conclusions: Overall, our findings highlight the significant impact of colistin use regulations on the decreased prevalence of colistin-resistant E. coli among Ecuadorian residents.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Infection and Chemotherapy INFECTIOUS DISEASES-PHARMACOLOGY & PHARMACY

CiteScore

4.10

自引率

4.50%

发文量

303

审稿时长

47 days

期刊介绍： The Journal of Infection and Chemotherapy (JIC) — official journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases — welcomes original papers, laboratory or clinical, as well as case reports, notes, committee reports, surveillance and guidelines from all parts of the world on all aspects of chemotherapy, covering the pathogenesis, diagnosis, treatment, and control of infection, including treatment with anticancer drugs. Experimental studies on animal models and pharmacokinetics, and reports on epidemiology and clinical trials are particularly welcome.